Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

When Global Blood Therapeutics (GBT) IPO'd last August, shares priced above their expected range at $20 and skyrocketed at the open to $34.

For Q1 2018 (ended on March 31), Global Blood Therapeutics posted $41.6M ($0.87 per share) net losses compared to $23.3M ($0.60 per share) declines (for the same period a year prior).

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

By Padmanabhan Ananthan (Reuters) -In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal in a late-stage trial for patients aged ...

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the presentation of a case study highlighting the effect of GBT440 ...

Shares of Global Blood Therapeutics Inc., based just outside San Francisco, rose more than 4% to $66.68 before the opening bell. Shares of Pfizer were essentially flat.

Shares of Global Blood Therapeutics Inc.(NASDAQ: GBT), a clinical-stage biotech developing new drugs to treat blood-based disorders, surged 47.1% higher in January, according to data from S&P ...

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic. Pfizer said ...

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and ...

* Global Blood Therapeutics Inc - ‍qtrly cash, cash equivalents, marketable securities $259.4 million at Sept 30, 2017 versus $197.3 million at Dec 31, 2016 Source text for Eikon: Further ...